Your browser doesn't support javascript.
loading
Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing.
Nahar, Rahul; Zhai, Weiwei; Zhang, Tong; Takano, Angela; Khng, Alexis J; Lee, Yin Yeng; Liu, Xingliang; Lim, Chong Hee; Koh, Tina P T; Aung, Zaw Win; Lim, Tony Kiat Hon; Veeravalli, Lavanya; Yuan, Ju; Teo, Audrey S M; Chan, Cheryl X; Poh, Huay Mei; Chua, Ivan M L; Liew, Audrey Ann; Lau, Dawn Ping Xi; Kwang, Xue Lin; Toh, Chee Keong; Lim, Wan-Teck; Lim, Bing; Tam, Wai Leong; Tan, Eng-Huat; Hillmer, Axel M; Tan, Daniel S W.
Affiliation
  • Nahar R; Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Singapore, 138672, Singapore.
  • Zhai W; Human Genetics, Genome Institute of Singapore, Singapore, 138672, Singapore.
  • Zhang T; School of Biological Sciences, Nanyang Technological University, Singapore, 637551, Singapore.
  • Takano A; Human Genetics, Genome Institute of Singapore, Singapore, 138672, Singapore.
  • Khng AJ; Department of Pathology, Singapore General Hospital, Singapore, 169608, Singapore.
  • Lee YY; Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Singapore, 138672, Singapore.
  • Liu X; Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Singapore, 138672, Singapore.
  • Lim CH; Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Singapore, 138672, Singapore.
  • Koh TPT; Department of Cardiothoracic Surgery, National Heart Centre Singapore, Singapore, 169609, Singapore.
  • Aung ZW; Department of Cardiothoracic Surgery, National Heart Centre Singapore, Singapore, 169609, Singapore.
  • Lim TKH; Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore, Singapore, 169610, Singapore.
  • Veeravalli L; Department of Pathology, Singapore General Hospital, Singapore, 169608, Singapore.
  • Yuan J; Research Pipeline Development, Genome Institute of Singapore, Singapore, 138672, Singapore.
  • Teo ASM; Cancer Stem Cell Biology, Genome Institute of Singapore, Singapore, 138672, Singapore.
  • Chan CX; Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Singapore, 138672, Singapore.
  • Poh HM; Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Singapore, 138672, Singapore.
  • Chua IML; Cancer Therapeutics and Stratified Oncology, Genome Institute of Singapore, Singapore, 138672, Singapore.
  • Liew AA; Next Generation Sequencing Platform, Genome Institute of Singapore, Singapore, 138672, Singapore.
  • Lau DPX; Cancer Stem Cell Biology, Genome Institute of Singapore, Singapore, 138672, Singapore.
  • Kwang XL; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, 169610, Singapore.
  • Toh CK; Cancer Therapeutics Research Laboratory, Division of Medical Sciences, National Cancer Centre Singapore, Singapore, 169610, Singapore.
  • Lim WT; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, 169610, Singapore.
  • Lim B; Cancer Therapeutics Research Laboratory, Division of Medical Sciences, National Cancer Centre Singapore, Singapore, 169610, Singapore.
  • Tam WL; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, 169610, Singapore.
  • Tan EH; Cancer Therapeutics Research Laboratory, Division of Medical Sciences, National Cancer Centre Singapore, Singapore, 169610, Singapore.
  • Hillmer AM; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, 169610, Singapore.
  • Tan DSW; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, 169610, Singapore.
Nat Commun ; 9(1): 216, 2018 01 15.
Article in En | MEDLINE | ID: mdl-29335443
ABSTRACT
EGFR-mutant lung adenocarcinomas (LUAD) display diverse clinical trajectories and are characterized by rapid but short-lived responses to EGFR tyrosine kinase inhibitors (TKIs). Through sequencing of 79 spatially distinct regions from 16 early stage tumors, we show that despite low mutation burdens, EGFR-mutant Asian LUADs unexpectedly exhibit a complex genomic landscape with frequent and early whole-genome doubling, aneuploidy, and high clonal diversity. Multiple truncal alterations, including TP53 mutations and loss of CDKN2A and RB1, converge on cell cycle dysregulation, with late sector-specific high-amplitude amplifications and deletions that potentially beget drug resistant clones. We highlight the association between genomic architecture and clinical phenotypes, such as co-occurring truncal drivers and primary TKI resistance. Through comparative analysis with published smoking-related LUAD, we postulate that the high intra-tumor heterogeneity observed in Asian EGFR-mutant LUAD may be contributed by an early dominant driver, genomic instability, and low background mutation rates.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenocarcinoma / Genomics / ErbB Receptors / Exome Sequencing / Lung Neoplasms / Mutation Limits: Humans Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2018 Document type: Article Affiliation country: Singapur

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenocarcinoma / Genomics / ErbB Receptors / Exome Sequencing / Lung Neoplasms / Mutation Limits: Humans Language: En Journal: Nat Commun Journal subject: BIOLOGIA / CIENCIA Year: 2018 Document type: Article Affiliation country: Singapur